<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberculin skin test: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberculin skin test: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tuberculin skin test: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10971" href="/d/html/10971.html" rel="external">see "Tuberculin skin test: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F232324"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aplisol;</li>
<li>Tubersol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868542"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tubersol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F232332"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F232325"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing below is based on US/Canadian products which contain the PPD-S formulation; in regions outside of North America other products may be used, including the RT 23 formulation, and standard doses may differ between products as the units are not equivalent (Yang 2012).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9a453f-4577-4fe0-838b-5eabb76c29f2">Tuberculin skin test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculin skin test:</b>
<b>Intradermal:</b> 5 units (0.1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>TST interpretation: Criteria for positive TST read at 48 to 72 hours (CDC 2020):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induration ≥5 mm: Patients with HIV infection (or risk factors for HIV infection, but unknown status), recent close contact to person with known tuberculosis (TB) disease (active TB), patients with chest x-ray consistent with prior TB, patients with organ transplants and other immunosuppressed patients (receiving the equivalent of prednisone ≥15 mg/day for ≥1 month or those taking TNF-α antagonists).</p>
<p style="text-indent:-2em;margin-left:6em;">Induration ≥10 mm: Patients with clinical conditions that increase risk of TB infection, people born in countries where TB disease is common, IV drug users, residents and employees of high-risk congregate settings, mycobacteriology laboratory workers, people &lt;90% of ideal body weight, children &lt;5 years of age, or infants, children, and adolescents exposed to adults at high risk</p>
<p style="text-indent:-2em;margin-left:6em;">Induration ≥15 mm: Patients who do not meet any of the above criteria (no risk factors for TB)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>TST interpretation (CDC guidelines) in a health care setting (CDC 2005): </b></p>
<p style="text-indent:-2em;margin-left:6em;">Baseline test: ≥10 mm is positive (either first or second step); 0 to 9 mm is negative</p>
<p style="text-indent:-2em;margin-left:6em;">Serial testing without known exposure: Increase of ≥10 mm is positive</p>
<p style="text-indent:-2em;margin-left:6em;">Known exposure:</p>
<p style="text-indent:-2em;margin-left:8em;">≥5 mm is positive in patients with baseline of 0 mm</p>
<p style="text-indent:-2em;margin-left:8em;">≥10 mm is positive in patients with negative baseline or previous screening result of &gt;0 mm</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990227"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987537"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F232326"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F232329"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9a453f-4577-4fe0-838b-5eabb76c29f2">Tuberculin skin test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculin skin test:</b> Intradermal: Infants ≥6 months, Children, and Adolescents: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193061"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193062"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F232305"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Presyncope, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash, localized erythema, localized vesiculation, rash at injection site, skin rash, skin ulceration at injection site, urticaria at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reactions, discomfort at injection site, hematoma at injection site, injection site scarring, local pruritus, localized edema, local tissue necrosis, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, stridor</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F232317"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tuberculin purified protein derivative (PPD) or any component of the formulation; previous severe reaction to tuberculin PPD skin test (TST); documented active TB or clear history of treatment for TB infection or disease; extensive burns or eczema.</p></div>
<div class="block war drugH1Div" id="F232302"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Viral infections: Skin testing may be deferred with major viral infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Infants &lt;6 months of age may have an absent or delayed response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For intradermal administration only; do not administer IV, IM, or SUBQ. Epinephrine (1 mg/mL) should be available to treat possible allergic reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Patients with a previous severe reaction to TST (vesiculation, ulceration, necrosis) at the injection site should not receive tuberculin PPD again.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions decreasing response: Tuberculous or other bacterial infections, fungal infections, viral infection, live virus vaccination, malignancy, corticosteroids or immunosuppressive agents, chronic renal failure, severe protein depletion, afibrinogenemia, and other conditions that impair immune response may cause a decreased response to test.</p>
<p style="text-indent:-2em;margin-left:4em;">• False positive reaction: A false positive reaction may occur in patients with nontuberculosis mycobacteria infection and patients previously vaccinated with bacilli Calmette-Guerin.</p></div>
<div class="block foc drugH1Div" id="F232311"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intradermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aplisol: 5 units/0.1 mL (1 mL, 5 mL) [latex free; contains phenol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tubersol: 5 units/0.1 mL (1 mL, 5 mL) [contains phenol, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F232298"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324046"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aplisol Intradermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 unit/0.1 mL (per mL): $106.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tubersol Intradermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 unit/0.1 mL (per mL): $115.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868543"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intradermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tubersol: 5 units (1 mL, 5 mL) [contains phenol, polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F232314"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intradermal: </b>For intradermal administration only; do not administer IV, IM, or SUBQ. Administer to upper third of forearm (palm up) ≥2 inches from elbow, wrist, or other injection site. If neither arm can be used, may administer to back of shoulder (CDC 2005). Avoid skin that is red or swollen; avoid visible veins. Administer using <sup>1</sup>/<sub>4</sub>- to <sup>1</sup>/<sub>2</sub>-inch 27-gauge needle or finer tuberculin syringe (CDC 2005). Should form wheal (6 to 10 mm in diameter) as liquid is injected which will remain ~10 minutes. Avoid pressure or bandage at injection site. Should wheal fail to form, repeat the test immediately at another site, at least 2 inches from the first site and circle the second injection site as an indication that this is the site to be read. Document date and time of injection, person placing TST, location of injection site, and lot number of solution. Read test at 48 to 72 hours following placement. Test results should be documented in millimeters even if classified as negative. Erythema and redness of skin are not indicative of a positive test result.</p></div>
<div class="block admp drugH1Div" id="F52613987"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intradermal: For intradermal administration only; do not administer IV, IM, or SubQ. Administer to upper third of forearm (palm up) ≥2 inches from elbow, wrist, or other injection site. If neither arm can be used, may administer to back of shoulder (CDC 2005). Avoid skin that is red or swollen; avoid visible veins. Administer using <sup>1</sup>/<sub>4</sub>- to <sup>1</sup>/<sub>2</sub>-inch 27-gauge needle or finer tuberculin syringe (CDC 2005). Should form wheal (6 to 10 mm in diameter) as liquid is injected which will remain ~10 minutes. Avoid pressure or bandage at injection site. Should wheal fail to form, repeat the test immediately at another site, at least 2 inches from the first site and circle the second injection site as an indication that this is the site to be read. Document date and time of injection, person placing TST, location of injection site, and product manufacturer and lot number of solution (CDC 2005). Read test at 48 to 72 hours following placement. Test results should be documented in millimeters even if classified as negative. Erythema and redness of skin are not indicative of a positive test result.</p></div>
<div class="block use drugH1Div" id="F232312"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Tuberculosis skin test:</b> An aid in the diagnosis of tuberculosis (TB) infection.</p></div>
<div class="block mst drugH1Div" id="F232338"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aplisol may be confused with Anusol</p>
<p style="text-indent:-2em;margin-left:4em;">PPD (purified protein derivative tuberculin test) may be confused with IPV (inactivated poliovirus vaccine).</p>
<p style="text-indent:-2em;margin-left:4em;">PPD (purified protein derivative tuberculin test) may be confused with IIV (inactivated influenza vaccine).</p>
<p style="text-indent:-2em;margin-left:4em;">PPD (purified protein derivative tuberculin test) may be confused with PCV (pneumococcal conjugate vaccine, PCV13 is the correct abbreviation).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tuberculin products may be confused with tetanus toxoid products, poliovirus vaccine (inactivated), and influenza virus vaccine. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300188"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F232306"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): May diminish the diagnostic effect of Tuberculin Tests. Management: It is preferable to administer live vaccines simultaneously with tuberculin tests. If a live vaccine has been recently administered, the tuberculin skin test should be administered 4 to 6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F3466540"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Tuberculin skin tests are valid and acceptable for use during pregnancy. Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020). An evaluation of TB risk factors and TB testing is recommended as part of antenatal care when indicated (Miele 2020).</p></div>
<div class="block brc drugH1Div" id="F3466542"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tuberculin purified protein derivative (PPD) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering tuberculin tests to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F3466566"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for immediate hypersensitivity reactions for ~15 minutes following injection.</p></div>
<div class="block pha drugH1Div" id="F232301"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tuberculosis results in individuals becoming sensitized to certain antigenic components of the <i>M. tuberculosis</i> organism. Culture extracts called tuberculins are contained in tuberculin skin test preparations. Upon intracutaneous injection of these culture extracts, a classic delayed (cellular) hypersensitivity reaction occurs. This reaction is characteristic of a delayed course (peak occurs &gt;24 hours after injection, induration of the skin secondary to cell infiltration, and occasional vesiculation and necrosis). Delayed hypersensitivity reactions to tuberculin may indicate infection with a variety of nontuberculosis mycobacteria, or vaccination with the live attenuated mycobacterial strain of <i>M. bovis</i> vaccine, BCG, in addition to previous natural infection with <i>M. tuberculosis</i>.</p></div>
<div class="block phk drugH1Div" id="F232316"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Delayed hypersensitivity reactions: 5-6 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: 48-72 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Reactions subside over a few days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58885292"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tubersol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Aplisol (tuberculin purified protein derivative, diluted) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881762">
<a name="10881762"></a>Centers for Disease Control and Prevention; American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. <i>MMWR Recomm Rep</i>. 2000;49(RR-6):1-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/10881762/pubmed" id="10881762" target="_blank">10881762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20577159">
<a name="20577159"></a>Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States. 2010. <i>MMWR Recomm Rep</i>. 2010;59(RR-5):1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/20577159/pubmed" id="20577159" target="_blank">20577159</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Tuberculin skin testing fact sheet. <a href="https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf" target="_blank">https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf</a>. Published September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16382216">
<a name="16382216"></a>Jensen, PA, Lamber LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of <i>Mycobacterium tuberculosis</i> in health-care settings, 2005. <i>MMWR Recomm Rep.</i> 2005;30;54(RR-17):1-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/16382216/pubmed" id="16382216" target="_blank">16382216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tubersol (tuberculin purified protein derivative) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22762692">
<a name="22762692"></a>Yang H, Kruh-Garcia NA, Dobos KM. Purified protein derivatives of tuberculin--past, present, and future. <i>FEMS Immunol Med Microbiol</i>. 2012;66(3):273-280. doi: 10.1111/j.1574-695X.2012.01002.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tuberculin-skin-test-drug-information/abstract-text/22762692/pubmed" id="22762692" target="_blank">22762692</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10029 Version 168.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
